Michael Moore is a dedicated executive, currently serving as President at VMD. He began his career as a Respiratory Therapist and later transitioned to roles in sales and management, consistently achieving top performance in his field.

In December 2017, he joined VMD as President, bringing with him extensive experience from both the clinical and business sides of healthcare.

Prior to his role at VMD, he co-founded the Sleepco Subsidiaries and held key positions at PHM, including President, Interim CFO, and Managing Director, Disease Management, which have all contributed to his comprehensive expertise in the respiratory healthcare sector.

His educational background as a Respiratory Therapist from the California College of Health Science has been fundamental in shaping his professional journey and strategic vision, ensuring methodical and effective leadership at VMD.

Past Roles

Organization	Role	Date Range	Details
PHM (predecessor entity of VMD)	Managing Director, Disease Management	May 2015 - December 2017	Oversaw disease management strategies and operations
PHM (predecessor entity of VMD)	Interim Chief Financial Officer (CFO)	March 2016	Served following the sale of Sleepco Subsidiaries
PHM (predecessor entity of VMD)	President	May 2015	Assumed role after the sale of Sleepco Subsidiaries
Sleepco Subsidiaries	Co-founder	2006 - May 2015	Co-founded the company that was later sold to PHM
Praxair	Account Executive	N/A	Consistently exceeded sales goals and finished in the top 5 nationally
Praxair	Respiratory Therapist	N/A	Began his career in this role
Home Care Supply	Account Executive	N/A	Achieved similar sales success

Fixed Compensation

Data from FY 2024

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$446,477	Annual	Fixed annual salary approved in August 2024
All Other Compensation	$69,308	Annual	Additional benefits and perquisites
Termination Payment - Without Cause/Good Reason	$2,551,251	Upon termination event	Cash Severance: $912,374; Continued Benefits: $9,334; Accelerated Equity Awards: $1,629,543
Termination Payment - Without Cause in Connection with Change in Control	$3,012,105	Upon termination within 12 months of change in control	Cash Severance: $1,368,561; Continued Benefits: $14,001; Accelerated Equity Awards: $1,629,543
Termination Payment - Retirement/Death/Disability	$1,629,543	Upon retirement, death, or disability	Accelerated Equity Awards only: $1,629,543
Stock Awards (Restricted Stock Units)	$900,826	Vests equally over 3 years	80,527 RSUs granted on January 29, 2024
Phantom Share Plan Awards	$225,204	Not specified	26,842 units granted on January 29, 2024

Performance Compensation

Data from FY 2024

Corporation-wide Active Patient Bonus

Metric	Value	Additional Details
Bonus Amount ($)	$3,700	Paid equally to all qualifying employees; part of a company-wide initiative to enhance patient engagement

Nonequity Incentive Plan Compensation

Metric	Value	Additional Details
Actual Payout ($)	$593,043	Cash bonus paid lump sum within 2.5 months after fiscal year-end
Target Bonus ($)	$456,187	Baseline target under the Cash Bonus Plan
Maximum Bonus ($)	$684,281	Cap on bonus payout
Performance Metrics	- Adjusted EBITDA

Revenue
Business line growth
Number of patients (70% weight)
Capital deployment, technological capabilities, internal leadership, corporate governance, staffing levels (30% weight) | Metrics and weightings determined by the Compensation Committee; specific thresholds not detailed | | Evaluation Period | Fiscal Year 2024 | Performance measured over the plan year | | Vesting Schedule | N/A | As a cash bonus, no vesting applies |

The Nonequity Incentive Plan Compensation reflects performance that exceeded the target bonus but did not reach the maximum threshold.